Anti-AKT1 + AKT2 + AKT3 antibody [EPR16798] (Ab179463)
PKB, RAC, AKT1, RAC-alpha serine/threonine-protein kinase, Protein kinase B, Protein kinase B alpha, Proto-oncogene c-Akt, RAC-PK-alpha, PKB alpha, PKBG, AKT3, RAC-gamma serine/threonine-protein kinase, Protein kinase Akt-3, Protein kinase B gamma, RAC-PK-gamma, STK-2, PKB gamma, RAC-beta serine/threonine-protein kinase, Protein kinase Akt-2, Protein kinase B beta, RAC protein kinase beta, PKB beta, RAC-PK-beta, AKT2
详细信息
背景信息
What is this antibody validated in? Anti-AKT1 + AKT2 + AKT3 antibody [EPR16798] (ab179463) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Intra), Immunoprecipitation (IP), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF) in Human, Mouse, Rat, Xenopus laevis, Xenopus tropicalis samples. What is the molecular weight of AKT1 + AKT2 + AKT3? Anti-AKT1 + AKT2 + AKT3 [EPR16798] (ab179463) specifically detects a band for AKT1 + AKT2 + AKT3 (UniProt: P31749) at a molecular weight of 56kDa. Trusted by the scientific community Anti-AKT1 + AKT2 + AKT3 [EPR16798] (ab179463) was first used in a scientific publication in 2014 and has been cited over 310 times in peer-reviewed journals. Other related products We have a range of other formats of antibody clone [EPR16798] also available for your convenience: ab179463, PE - ab210454, Carrier free - ab214167, Carrier free - ab271930, Alexa Fluor® 647 - ab302553 Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents. What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies. Trial sizes available! Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 20µl. Discover our selection of trial-size antibodies.
文献引用 (415)
Exosomal lncRNA OTUD6B-AS1 as a pathogenic nanocarrier promotes inflammatory macrophage polarization in endometritis via a targetable ceRNA circuit.
外泌体 lncRNA OTUD6B-AS1 作为致病纳米载体，通过可靶向的 ceRNA 回路促进子宫内膜炎中的炎症巨噬细胞极化。
INHBA, regulated by C/EBPβ, induces M2 macrophage polarization to promote tumor metastasis and growth via activating the PI3K/AKT pathway in gastric cancer.
INHBA 受 C/EBPβ 调控，诱导 M2 巨噬细胞极化，通过激活胃癌中的 PI3K/AKT 通路促进肿瘤转移和生长。
Novel function of GTPBP2 in promoting hepatocellular carcinoma progression through inhibition of BTRC-mediated KRAS degradation.
GTPBP2 的新功能是通过抑制 BTRC 介导的 KRAS 降解来促进肝细胞癌的进展。
INPP5D/SHIP1-mediated immunometabolic remodeling of renal monocytes in idiopathic membranous nephropathy.
特发性膜性肾病中肾脏单核细胞的INPP5D/SHIP1介导的免疫代谢重塑。
ROCK inhibition promotes axon and myelin regeneration via PI3K/Akt/GSK3β in a mouse sciatic nerve injury model.
在小鼠坐骨神经损伤模型中，ROCK 抑制通过 PI3K/Akt/GSK3β 促进轴突和髓鞘再生。
Synergistic anti-hepatoma effect of triptolide and quercetin via co-inhibition and interaction with Janus kinase and mammalian target of rapamycin signal pathway.
雷公藤内酯醇和槲皮素通过与 Janus 激酶和哺乳动物雷帕霉素靶蛋白信号通路的共同抑制和相互作用，发挥协同抗肝癌作用。
FGFR2 is a Candidate Immune-Associated Marker of Diabetic Foot Ulcer That Promotes Keratinocyte Function by Activating the PI3K/Akt and MAPK Pathways.
FGFR2 是糖尿病足溃疡的候选免疫相关标志物，它通过激活 PI3K/Akt 和 MAPK 通路促进角质形成细胞功能。
Obovatol induces apoptosis in breast cancer by downregulating the PI3K/Akt pathway.
Obovatol 通过下调 PI3K/Akt 通路诱导乳腺癌细胞凋亡。
Cinobufotalin reduces glioblastoma resistance to temozolomide by inhibiting the CCL5-mediated PI3K/Akt/mTOR signaling pathway.
蟾毒灵通过抑制 CCL5 介导的 PI3K/Akt/mTOR 信号通路来降低胶质母细胞瘤对替莫唑胺的耐药性。
Inhibition of ARH2 by pH/ROS-responsive nanosystem for improved lung adenocarcinoma immunochemotherapy.
利用 pH/ROS 响应纳米系统抑制 ARH2 以改善肺腺癌免疫化疗
- 1
- 2
- 3
- 4
- 5
- 6
- 42